The Science
of Nivalis

Nivalis Science

Nivalis is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of novel therapeutics for patients with cystic fibrosis (CF). Our lead product candidate, cavosonstat (N91115), is an investigational small molecule that has the potential to address a defect in the cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene, the underlying cause of CF. The lead candidate is being evaluated in a Phase 2 clinical study in people with CF.


Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.